Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — Marts 2022

Biotek-snakken — Marts 2022

Planlagt Fastgjort Låst Flyttet Biotek-snakken
87 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #58

    Just a moment...

    favicon

    (www.fiercebiotech.com)

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #59

      Men lidt voldsom reaktion tænker jeg, men i dette sure marked, så er det bare sådan det er desværre

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #60

        Orphazyme trækker ansøgning for Arimoclomol i Europa - NY https://proinvestor.com/investornyt/798629/orphazyme-traekker-ansogning-for-arimoclomol-i-europa-ny

        1 Reply Last reply
        0
        • L Offline
          L Offline
          LP90
          wrote on sidst redigeret af
          #61

          Sukkeralf tusinde tak for dit svar god dag 🙂

          1 Reply Last reply
          0
          • 2 Offline
            2 Offline
            2311leeds
            wrote on sidst redigeret af
            #62

            Er der stadig muligheder i Orphazyme A/S?Eller er selskabet ved at dø helt??

            1 Reply Last reply
            0
            • F Offline
              F Offline
              Fandel
              wrote on sidst redigeret af
              #63

              Godmorgen...

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #64

                Lidt mere om ImmunoGens data:

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #65

                  https://firstwordpharma.com/story/5530631'

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #66

                    Prior to these latest data, one expert had told FirstWord “so far the only thing we hear are excuses why it is not as good as it should be. It may be only a poor development strategy, but it could also be that the drug is not as good as expected. We’ve also had negative trials with other drugs targeting the folate receptor, which were close to registration but in the end failed. I’m still not convinced of this approach."

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #67

                      New data, which at the very least raises question marks about mirvetuximab soravtansine in the eyes of investors, means ImmunoGen could face a bumpy six months.

                      1 Reply Last reply
                      0
                      • F Offline
                        F Offline
                        Fandel
                        wrote on sidst redigeret af
                        #68

                        Godmorgen...

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #69

                          Kort video: Jeg orienterer om overflytningen af ProInvestor til en ny platform. Der lys forude. :−) I disse tider med krig, rentestigninger osv. kan det være svært at navigere som aktieinvestor. Jeg guider til gode input ift. situationen i Ukraine og Rusland og inspiration til, hvad man kan gøre med sin portefølje i en svær tid, med Hans-Henrik Nielsen fra Markettimer. https://www.proinvestor.com/boards/102348

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #70

                            SUPPORT-ABONNEMENT - Støt Proinvestor.com: https://www.proinvestor.com/donation

                            1 Reply Last reply
                            0
                            • F Offline
                              F Offline
                              Fandel
                              wrote on sidst redigeret af
                              #71

                              Godmorgen...

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #72

                                NBI ved at bunde ud https://www.proinvestor.com/boards/102420/NBI-ved-at-bunde-ud

                                1 Reply Last reply
                                0
                                • F Offline
                                  F Offline
                                  Fandel
                                  wrote on sidst redigeret af
                                  #73

                                  Godmorgen...

                                  1 Reply Last reply
                                  0
                                  • F Offline
                                    F Offline
                                    Fandel
                                    wrote on sidst redigeret af
                                    #74

                                    Godmorgen...

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #75

                                      Biotech Stocks Facing FDA Decision In April 2022 https://proinvestor.com/investornyt/801042/biotech-stocks-facing-fda-decision-in-april-2022

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #76

                                        SynAct vil hente millioner på aktieemission https://proinvestor.com/investornyt/801047/synact-vil-hente-millioner-pa-aktieemission

                                        1 Reply Last reply
                                        0
                                        • L Offline
                                          L Offline
                                          lahn1
                                          wrote on sidst redigeret af
                                          #77

                                          SUTRO - er det ikke muligt at faldet forleden er udtryk for skepsis til FRa som target pga SORAYA og resultatet (andre mislykkede trials) samtidigt med at Bev gives skylden for kort PFS, som STR002 har et combo studie med. STRO-002 havde 70% prior Bev pts med i dose esc. og 63% prior Bev i dose exp. Har desværre ikke indsigt i Bev indvirken på PFS. Vi kan jo håbe på at det bare en dårligt undskyldning for at mirv ikke er super godt. idk ?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper